These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38858097)

  • 1. Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial.
    Xiong Y; Wang L; Pan Y; Wang M; Schwamm LH; Duan C; Campbell BCV; Li S; Hao M; Wu N; Cao Z; Wu S; Li Z; Wang Y
    Stroke Vasc Neurol; 2024 Jun; ():. PubMed ID: 38858097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
    Wang Y; Li S; Pan Y; Li H; Parsons MW; Campbell BCV; Schwamm LH; Fisher M; Che F; Dai H; Li D; Li R; Wang J; Wang Y; Zhao X; Li Z; Zheng H; Xiong Y; Meng X;
    Lancet; 2023 Feb; 401(10377):645-654. PubMed ID: 36774935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trial.
    Nair R; Singh N; Kate M; Asdaghi N; Sarmiento R; Bala F; Coutts SB; Horn M; Poppe AY; Williams H; Ademola A; Alhabli I; Benali F; Khosravani H; Hunter G; Tkach A; Manosalva Alzate HA; Pikula A; Field T; Trivedi A; Dowlatshahi D; Catanese L; Shuaib A; Demchuk A; Sajobi T; Almekhlafi MA; Swartz RH; Menon B; Buck BH
    Stroke Vasc Neurol; 2024 Jan; ():. PubMed ID: 38296590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial.
    Muir KW; Ford GA; Ford I; Wardlaw JM; McConnachie A; Greenlaw N; Mair G; Sprigg N; Price CI; MacLeod MJ; Dima S; Venter M; Zhang L; O'Brien E; Sanyal R; Reid J; Sztriha LK; Haider S; Whiteley WN; Kennedy J; Perry R; Lakshmanan S; Chakrabarti A; Hassan A; Marigold R; Raghunathan S; Sims D; Bhandari M; Wiggam I; Rashed K; Douglass C;
    Lancet Neurol; 2024 Nov; 23(11):1087-1096. PubMed ID: 39424558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial.
    Li S; Wangqin R; Pan Y; Jin A; Li H; Schwamm LH; Fisher M; Campbell BCV; Parsons MW; Wang Z; Dai H; Li D; Li R; Wang J; Wang D; Wang Y; Zhao X; Li Z; Zheng H; Xiong Y; Meng X; Wang Y
    Stroke Vasc Neurol; 2024 Jan; ():. PubMed ID: 38296586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial.
    Parsons MW; Yogendrakumar V; Churilov L; Garcia-Esperon C; Campbell BCV; Russell ML; Sharma G; Chen C; Lin L; Chew BL; Ng FC; Deepak A; Choi PMC; Kleinig TJ; Cordato DJ; Wu TY; Fink JN; Ma H; Phan TG; Markus HS; Molina CA; Tsai CH; Lee JT; Jeng JS; Strbian D; Meretoja A; Arenillas JF; Buck BH; Devlin MJ; Brown H; Butcher KS; O'Brien B; Sabet A; Wijeratne T; Bivard A; Grimley RS; Agarwal S; Munshi SK; Donnan GA; Davis SM; Miteff F; Spratt NJ; Levi CR;
    Lancet Neurol; 2024 Aug; 23(8):775-786. PubMed ID: 38880118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
    Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L
    Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
    Menon BK; Buck BH; Singh N; Deschaintre Y; Almekhlafi MA; Coutts SB; Thirunavukkarasu S; Khosravani H; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar J; Williams H; Field TS; Manosalva A; Siddiqui M; Zafar A; Imoukhuede O; Hunter G; Demchuk AM; Mishra S; Gioia LC; Jalini S; Cayer C; Phillips S; Elamin E; Shoamanesh A; Subramaniam S; Kate M; Jacquin G; Camden MC; Benali F; Alhabli I; Bala F; Horn M; Stotts G; Hill MD; Gladstone DJ; Poppe A; Sehgal A; Zhang Q; Lethebe BC; Doram C; Ademola A; Shamy M; Kenney C; Sajobi TT; Swartz RH;
    Lancet; 2022 Jul; 400(10347):161-169. PubMed ID: 35779553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
    Logallo N; Novotny V; Assmus J; Kvistad CE; Alteheld L; Rønning OM; Thommessen B; Amthor KF; Ihle-Hansen H; Kurz M; Tobro H; Kaur K; Stankiewicz M; Carlsson M; Morsund Å; Idicula T; Aamodt AH; Lund C; Næss H; Waje-Andreassen U; Thomassen L
    Lancet Neurol; 2017 Oct; 16(10):781-788. PubMed ID: 28780236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial.
    Meng X; Li S; Dai H; Lu G; Wang W; Che F; Geng Y; Sun M; Li X; Li H; Wang Y
    JAMA; 2024 Nov; 332(17):1437-1445. PubMed ID: 39264623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
    Bivard A; Zhao H; Churilov L; Campbell BCV; Coote S; Yassi N; Yan B; Valente M; Sharobeam A; Balabanski AH; Dos Santos A; Ng JL; Yogendrakumar V; Ng F; Langenberg F; Easton D; Warwick A; Mackey E; MacDonald A; Sharma G; Stephenson M; Smith K; Anderson D; Choi P; Thijs V; Ma H; Cloud GC; Wijeratne T; Olenko L; Italiano D; Davis SM; Donnan GA; Parsons MW;
    Lancet Neurol; 2022 Jun; 21(6):520-527. PubMed ID: 35525251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
    Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW
    Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world comparative safety and efficacy of tenecteplase
    Psychogios K; Palaiodimou L; Katsanos AH; Magoufis G; Safouris A; Kargiotis O; Spiliopoulos S; Papageorgiou E; Theodorou A; Voumvourakis K; Broutzos E; Stamboulis E; Tsivgoulis G
    Ther Adv Neurol Disord; 2021; 14():1756286420986727. PubMed ID: 33488774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial.
    Singh N; Almekhlafi MA; Bala F; Ademola A; Coutts SB; Deschaintre Y; Khosravani H; Buck B; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar JJ; Ghrooda E; Poppe AY; Williams H; Field TS; Manosalva A; Siddiqui MM; Zafar A; Imoukhoude O; Hunter G; Shamy M; Demchuk AM; Claggett BL; Hill MD; Sajobi TT; Swartz RH; Menon BK
    Stroke; 2023 Nov; 54(11):2766-2775. PubMed ID: 37800372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke.
    Tsivgoulis G; Katsanos AH; Christogiannis C; Faouzi B; Mavridis D; Dixit AK; Palaiodimou L; Khurana D; Petruzzellis M; Psychogios K; Macleod MJ; Ahmed N
    Ann Neurol; 2022 Sep; 92(3):349-357. PubMed ID: 35713213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.
    Roaldsen MB; Eltoft A; Wilsgaard T; Christensen H; Engelter ST; Indredavik B; Jatužis D; Karelis G; Kõrv J; Lundström E; Petersson J; Putaala J; Søyland MH; Tveiten A; Bivard A; Johnsen SH; Mazya MV; Werring DJ; Wu TY; De Marchis GM; Robinson TG; Mathiesen EB;
    Lancet Neurol; 2023 Feb; 22(2):117-126. PubMed ID: 36549308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration.
    Warach SJ; Ranta A; Kim J; Song SS; Wallace A; Beharry J; Gibson D; Cadilhac DA; Bladin CF; Kleinig TJ; Harvey J; Palanikumar L; Doss VT; Marescalco R; Fink JN; Tyson A; Schlick KH; Noh L; Wilson D; Figueroa S; Pech MA; Paletz LB; Lewis MK; Castro M; Sahlein DH; Lafranchise EF; Sandall J; Asif KS; Geraghty SR; Cullis PA; Malisch T; Neill TA; LaMonte MP; Campbell BCV; Wu TY
    JAMA Neurol; 2023 Jul; 80(7):732-738. PubMed ID: 37252708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenecteplase and Alteplase for Thrombolysis of Acute Ischemic Stroke within 4.5 Hours: An Efficacy and Safety Study.
    Dhar N; Kumar M; Tiwari A; Desai I; Madhaw G; Kumar N
    Ann Indian Acad Neurol; 2022; 25(5):897-901. PubMed ID: 36561006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke.
    Logallo N; Kvistad CE; Nacu A; Naess H; Waje-Andreassen U; Asmuss J; Aamodt AH; Lund C; Kurz MW; Rønning OM; Salvesen R; Idicula TT; Thomassen L
    BMC Neurol; 2014 May; 14():106. PubMed ID: 24886064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol.
    Bivard A; Garcia-Esperon C; Churilov L; Spratt N; Russell M; Campbell BC; Choi P; Kleinig T; Ma H; Markus H; Molina C; Hsu C; Tsai CH; Meretoja A; Strbian D; Butcher K; Wu T; Davis S; Donnan G; Levi C; Parsons M
    Int J Stroke; 2023 Jul; 18(6):751-756. PubMed ID: 36655938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.